Clopidogrel BMS

RSS
Withdrawn

This medicine's authorisation has been withdrawn

clopidogrel
MedicineHumanWithdrawn
  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 16 July 2008 the European Commission issued a marketing authorisation valid throughout the European Union for the medicinal product Clopidogrel BMS, clopidogrel, which had been approved for the prevention of atherothrombotic events in:

  • Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
  • Patients suffering from acute coronary syndrome: Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA). ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy. 

The marketing authorisation holder (MAH) responsible for Clopidogrel BMS was Bristol Myers Squibb Pharma EEIG. The European Commission was notified by letter dated 20 October 2009 of the MAH’s decision to voluntarily withdraw the marketing authorisation for Clopidogrel BMS for commercial reasons. 

On 12 November 2009 the European Commission issued a decision to withdraw the marketing authorisation for Clopidogrel BMS. Pursuant to this decision the European Public Assessment Report for Clopidogrel BMS is updated to reflect that the marketing authorisation is no longer valid.

български (BG) (441.64 KB - PDF)

View

español (ES) (270.83 KB - PDF)

View

čeština (CS) (415.4 KB - PDF)

View

dansk (DA) (271.04 KB - PDF)

View

Deutsch (DE) (272.03 KB - PDF)

View

eesti keel (ET) (269.11 KB - PDF)

View

ελληνικά (EL) (478.25 KB - PDF)

View

français (FR) (271.98 KB - PDF)

View

italiano (IT) (270.07 KB - PDF)

View

latviešu valoda (LV) (413.55 KB - PDF)

View

lietuvių kalba (LT) (633.98 KB - PDF)

View

magyar (HU) (402.65 KB - PDF)

View

Malti (MT) (413.05 KB - PDF)

View

Nederlands (NL) (270.69 KB - PDF)

View

polski (PL) (419.76 KB - PDF)

View

português (PT) (271.17 KB - PDF)

View

română (RO) (380.18 KB - PDF)

View

slovenčina (SK) (430.76 KB - PDF)

View

slovenščina (SL) (366.07 KB - PDF)

View

Suomi (FI) (271.02 KB - PDF)

View

svenska (SV) (269.45 KB - PDF)

View

Product information

български (BG) (851.28 KB - PDF)

View

español (ES) (719.8 KB - PDF)

View

čeština (CS) (844.3 KB - PDF)

View

dansk (DA) (695.96 KB - PDF)

View

Deutsch (DE) (738.88 KB - PDF)

View

eesti keel (ET) (668.61 KB - PDF)

View

ελληνικά (EL) (1.03 MB - PDF)

View

français (FR) (736.31 KB - PDF)

View

italiano (IT) (714.25 KB - PDF)

View

latviešu valoda (LV) (915.72 KB - PDF)

View

lietuvių kalba (LT) (1.24 MB - PDF)

View

magyar (HU) (782.77 KB - PDF)

View

Malti (MT) (827.24 KB - PDF)

View

Nederlands (NL) (693.25 KB - PDF)

View

polski (PL) (936.49 KB - PDF)

View

português (PT) (691.04 KB - PDF)

View

română (RO) (824.44 KB - PDF)

View

slovenčina (SK) (825.02 KB - PDF)

View

slovenščina (SL) (765.81 KB - PDF)

View

Suomi (FI) (677.55 KB - PDF)

View

svenska (SV) (664.87 KB - PDF)

View
Latest procedure affecting product information: N/0012
26/10/2009
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (350.69 KB - PDF)

View

español (ES) (229.27 KB - PDF)

View

čeština (CS) (317.55 KB - PDF)

View

dansk (DA) (251.25 KB - PDF)

View

Deutsch (DE) (227.85 KB - PDF)

View

eesti keel (ET) (228.82 KB - PDF)

View

ελληνικά (EL) (324.29 KB - PDF)

View

français (FR) (229.2 KB - PDF)

View

italiano (IT) (228.11 KB - PDF)

View

latviešu valoda (LV) (321.11 KB - PDF)

View

lietuvių kalba (LT) (532.46 KB - PDF)

View

magyar (HU) (318.5 KB - PDF)

View

Malti (MT) (316.67 KB - PDF)

View

Nederlands (NL) (227.21 KB - PDF)

View

polski (PL) (281.38 KB - PDF)

View

português (PT) (251.2 KB - PDF)

View

română (RO) (313.4 KB - PDF)

View

slovenčina (SK) (281.55 KB - PDF)

View

slovenščina (SL) (271.82 KB - PDF)

View

Suomi (FI) (228.72 KB - PDF)

View

svenska (SV) (250.54 KB - PDF)

View

Product details

Name of medicine
Clopidogrel BMS
Active substance
clopidogrel (as hydrogen sulfate)
International non-proprietary name (INN) or common name
clopidogrel
Therapeutic area (MeSH)
  • Stroke
  • Peripheral Vascular Diseases
  • Myocardial Infarction
  • Acute Coronary Syndrome
Anatomical therapeutic chemical (ATC) code
B01AC04

Pharmacotherapeutic group

Antithrombotic agents

Therapeutic indication

Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:

- Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.

- Patients suffering from acute coronary syndrome:

Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).

ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.

Authorisation details

EMA product number
EMEA/H/C/000974
Marketing authorisation holder
Bristol-Myers Squibb Pharma EEIG

Plaza 254
Blanchardstown Corporate Park 2
Dublin 15
D15 T867
Ireland

Marketing authorisation issued
16/07/2008
Withdrawal of marketing authorisation
12/11/2009
Revision
3

Assessment history

This page was last updated on

Share this page